Bazedoxifene News
Bazedoxifene currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Bazedoxifene with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated;...
- Evidence level: L5
- Predicted indications (20):
- heparin cofactor 2 deficiency (99.0%)
- postmenopausal osteoporosis (98.8%)
- antithrombin deficiency type 2 (98.7%)
- Worth syndrome (98.6%)
- amenorrhea (disease) (98.5%)
- factor 5 excess with spontaneous thrombosis (98.4%)
- pregnancy associated osteoporosis (98.3%)
- autosomal dominant neovascular inflammatory vitreoretinopathy (98.2%)
- thrombophilia (97.7%)
- primary release disorder of platelets (97.5%)
- pseudo-von Willebrand disease (97.4%)
- succinyl-CoA:3-ketoacid CoA transferase deficiency (97.3%)
- severe nonproliferative diabetic retinopathy (96.7%)
- acne (disease) (96.2%)
- Glanzmann thrombasthenia (94.6%)
- drug-induced osteoporosis (93.7%)
- duodenal ulcer (disease) (91.2%)
- duodenogastric reflux (89.8%)
- fetal and neonatal alloimmune thrombocytopenia (89.8%)
- duodenal obstruction (89.6%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.